Last update 05 Jun 2025

Cabazitaxel Acetone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cabazitaxel, Cabazitaxel acetonate, DEP® cabazitaxel
+ [18]
Target
Action
inhibitors
Mechanism
Tubulin inhibitors
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC48H63NO15
InChIKeyJXGFNOAMBPABCK-JVXKREHESA-N
CAS Registry1426815-65-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Prostatic Cancer
Japan
04 Jul 2014
Metastatic castration-resistant prostate cancer
United States
17 Jun 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of prostatePhase 3
France
01 Dec 2013
Localized Prostate CarcinomaPhase 3
France
01 Dec 2013
Transitional Cell CarcinomaPhase 3
United Kingdom
01 Jan 2013
Castration-Resistant Prostatic CancerPhase 3
United States
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
United States
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
United States
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
Japan
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
Japan
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
Japan
05 May 2011
Castration-Resistant Prostatic CancerPhase 3
Denmark
05 May 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
dezhvgcoom(dueaaxpwiv) = mvsnpjmyqu ugsjctkino (abeubkeajp, 6.6 - 10.8)
Positive
30 May 2025
dezhvgcoom(dueaaxpwiv) = mfhvytngju ugsjctkino (abeubkeajp, 8.9 - 12.8)
Phase 2
Prostatic Cancer
Maintenance
120
saubuqdris(jvibricuqw) = quhthooupt vpbgfstyyp (jwqpfuqbxk, 2.0 - 4.4)
Positive
30 May 2025
lubtpgtfas(ugbesaeuqr) = pncioskmjy xoodymmkcc (gobnzuhsau, 6.4 - 19.6)
Not Applicable
-
First line of therapy
vtftzmdeoo(pgcltymwnp) = ezqbnoqbkb xkwadfkyum (aendnidwrr, 9.5 - 14)
-
13 Feb 2025
Second line of therapy
vtftzmdeoo(pgcltymwnp) = qktktlivma xkwadfkyum (aendnidwrr, 6.6 - 8.4)
Phase 2
81
(Abiraterone Acetate 1000 mg po Daily + Prednisone 5 mg po BID)
picihiyxdn(mpkphwvyrp) = tbmrwrwcee ymhwmeponu (iswxcctaxz, fxldqszwaf - qmjazeyhsf)
-
10 Dec 2024
(Cabazitaxel 25 mg/m2 IV + Abiraterone Acetate 1000 mg po Daily)
picihiyxdn(mpkphwvyrp) = objaoctewo ymhwmeponu (iswxcctaxz, ioxnhaqvax - wonfszjrll)
Phase 2
33
cabazitaxell cabazitaxelcisplatinbine, and cisplatin (CGC)
vxvfabovrk(jxlvzybbij) = glmnmuderk hzgajqsegw (ifduhbbhop )
Positive
15 Sep 2024
Phase 3
194
Triweekly 25mg/m2 cabazitaxel
qosigzuhuu(siqzplwudh) = bvbbzcvxfa sbncvbjyww (cjugdvkryj, 17.4 - 29.8)
Positive
15 Sep 2024
Biweekly 16mg/m2 cabazitaxel
qosigzuhuu(siqzplwudh) = yrmjgocoav sbncvbjyww (cjugdvkryj )
Phase 2
223
kaubfktgui(jodvpsnokz) = yuronrxlky ronuetrnkj (gkwzgzhlpi, 9.9 - 18.6)
Negative
02 Jun 2024
kaubfktgui(jodvpsnokz) = dckyblmgop ronuetrnkj (gkwzgzhlpi, 7.0 - 12.6)
Phase 1/2
75
kbncvlmfau(quwolfvhnh) = Treatment related adverse events (TRAEs) were mostly mild/moderate (grade (G) 1/2; 64%/25%). Only 21% of pts had G 3/4 non-hematological TRAEs, while G3/4 lab detected neutropenia was seen in only 23% of pts despite no routine G-CSF. TRAEs observed in ≥10% of pts included fatigue, neutropenia, anemia, thrombocytopenia, diarrhea, nausea, vomiting, peripheral neuropathy and decreased appetite. cwpiodyari (iwexycplsb )
Positive
24 May 2024
Phase 2
40
sdlocthxbr(ffjkceflve) = qoosstgvor qnhafchbxt (bxbuwsmvmf, thubqfeecj - urdtzyeies)
-
07 Feb 2024
Phase 1/2
15
kbbmqhrkcy(scsgpyzqbz) = jvzaboqoyk qvgthebdiw (nxuvoyonez )
Positive
18 Jan 2024
(EG ADENOCA pts)
kbbmqhrkcy(scsgpyzqbz) = cpgkactuxo qvgthebdiw (nxuvoyonez )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free